{"ticker": {"uuid": "26217278-1163-474b-86e4-9fa390517fd6", "symbol": "ANAB", "name": "AnaptysBio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "AnaptysBio (NASDAQ:ANAB) Trading 5.3% Higher - Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPZFd4U0FwS2dOOVVsTFlYODdTUnliYlk4ZVFrQ09DOXhNdGh5anBrX3V0cWQ5bUtLNlFFUkNqR3BGMjlqMU5nbzFlN3JsOWNiOUZ1ZFFnM3hIcUNNVURjN2dmT0NMOGk0SGRsemFNUTRKSHBDOW5JVFJfVWtiVGMxdldNVVhZWHdZOFZlS2hWRHU3dk1Ud3QtVzR3Z2pSRE5ONTVIdm5uWTFBNHNk?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T17:00:02+00:00", "published_display": "17 Jul 2026 17:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?", "summary": "AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current p", "url": "https://www.sahmcapital.com/news/content/is-anaptysbio-anab-undervalued-following-its-jemperli-royalty-appeal-and-gsk-trial-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T10:41:34", "published_display": "16 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ:ANAB) Shares Gap Down - What's Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQZ0Iydmh4Y1prbkNzanZObWRmRnhBRWdaSW56Wm5nVlpaT1pBSVMwRV9EVmhFS1pvUDVvc1k2aXV4UEZiZXptY0xMRWdQMkFqQ1dtbXFCRlB1RmdxcUF1RzNmbUJfUjh4aEZub3ZqQnNYNDd4TENDWHZZbDJZdmhaRzQ5bUlKNmlfZnlXaUhPWWtTZDgxdHpFaWFUZmozX3dodkhKSQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-15T16:05:51+00:00", "published_display": "15 Jul 2026 16:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10%", "summary": "AnaptysBio (ANAB) shares fell by 10.8% on July 15, 2026, closing at $55.76, amidst broader market volatility and investor caution in the biotechnology sector. The company, a clinical-stage biotech developing antibody product candidates, has a market capitalization of $1.67 billio", "url": "https://www.gurufocus.com/news/8960404/significant-decline-for-anaptysbio-anab-as-shares-drop-over-10?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T15:16:39", "published_display": "15 Jul 2026 15:16", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75", "summary": "Barclays has reiterated its Buy rating on AnaptysBio (ANAB.US), maintaining a target price of $75. This continued positive outlook suggests the firm sees potential upside for the biotechnology company's stock.", "url": "https://www.moomoo.com/news/post/72922436/barclays-maintains-anaptysbio-anabus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-15T01:41:34", "published_display": "15 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ:ANAB) Shares Down 7% - Time to Sell?", "summary": "AnaptysBio (NASDAQ:ANAB) shares dropped 7% in Tuesday trading, hitting an intraday low of $65.76. Despite a wider-than-expected Q1 loss, analysts maintain a \"Moderate Buy\" rating with an average price target of $81.82, and the company has authorized a $100 billion stock repurchas", "url": "https://www.marketbeat.com/instant-alerts/anaptysbio-nasdaqanab-shares-down-7-time-to-sell-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T18:11:53", "published_display": "14 Jul 2026 18:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes AnaptysBio (ANAB) an Investment Bet?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOTk8tQ3BZX29WNVBmOV9DYjhMTXdEeldxU0w3WTlKS1dGTHdHT0Q3ZUowNE1vX3JlNDIzbUhzcWVEQ1pwb1lsaFZvSmdaZHBleVFTQ2h2S1ZpMUxNTTZmTjNPQ2V0WExrdUQxellXVDdvRkRERDhFS3VtNW56Nll6Z0l3NU5JSFN2WnBteGhJVGY3Wm9yeUZpY0kxYkJSQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T14:56:40+00:00", "published_display": "14 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ANAPTYSBIO For: 13 July By Investing.com", "summary": "This article reports on a Form 144 filing for ANAPTYSBIO on July 13. It is a brief, factual announcement from Investing.com, providing no additional details beyond the filing date and company name. The article's content is minimal, serving primarily as an informational update.", "url": "https://ng.investing.com/news/stock-market-news/form-144-anaptysbio-for-13-july-93CH-2597508", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:12:44", "published_display": "13 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise", "summary": "JOE ANTHONY WARE, an insider at AnaptysBio (ANAB), has filed a Form 144 to sell 10,694 shares of common stock with an aggregate market value of $718,333.09. These shares are related to a stock option exercise and are expected to be sold on or after July 13, 2026, on NASDAQ. This ", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-aa9871dfbf36.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:33", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "summary": "AnaptysBio, Inc. (NASDAQ:ANAB) has received a \"Moderate Buy\" consensus recommendation from thirteen brokerages, with an average 12-month price target of $81.82. Analyst ratings have been mixed, with some price target increases and some downgrades, indicating ongoing debate about ", "url": "https://www.marketbeat.com/instant-alerts/anaptysbio-inc-nasdaqanab-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T06:39:20", "published_display": "10 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should AnaptysBio\u2019s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base?", "summary": "AnaptysBio (ANAB) was removed from several Russell indices in June 2026, which may impact its short-term trading liquidity and passive fund ownership. Despite this, the core investment thesis remains centered on its immunology pipeline and collaborations, with ongoing litigation ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/should-anaptysbios-anab-russell-index-removal-prompt-a-rethi", "source_name": "Simply Wall Street", "published_at": "2026-07-08T05:11:23", "published_display": "08 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) Undervalued As Russell Index Deletions Reshape Trading Flows?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. Financial Disclosures & Filings", "summary": "This page provides a comprehensive list of AnaptysBio, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategic decisions. It highlights key events such as earnings reports, corporate presentations, and conference transcr", "url": "https://www.tradingview.com/symbols/TRADEGATE-AN6/documents/", "source_name": "TradingView", "published_at": "2026-07-01T21:09:54", "published_display": "01 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ANAPTYSBIO, INC SEC Filing", "summary": "This article details an SEC Form 144 filing by AnaptysBio, Inc. (ANAB) concerning a proposed sale of securities. The document indicates a neutral filing impact and sentiment, outlining the filer and issuer information, as well as details about the common stock to be sold by Morga", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-c46f3e92c4ec.html", "source_name": "Stock Titan", "published_at": "2026-07-01T09:40:58", "published_display": "01 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "This article provides the enterprise value to revenue forward for AnaptysBio, Inc. (NASDAQ: ANAB). It presents a financial metric related to the company's valuation, indicating its enterprise value relative to its future anticipated revenue. The information is sourced from Tradin", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T23:10:24", "published_display": "30 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio\u2019s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?", "summary": "AnaptysBio (ANAB) was recently removed from several Russell indices and entered a one-year sublease agreement for its San Diego facility. These actions suggest a strategic shift involving optimized real estate commitments and a reframing of its investment narrative. Investors sho", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/is-anaptysbios-anab-index-exit-and-office-sublease-quietly-r", "source_name": "Simply Wall Street", "published_at": "2026-06-30T15:10:37", "published_display": "30 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "The article focuses on the \"Price to book forward\" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It provides a view of this financial indicator on the TradingView platform, noting that the market is closed and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T11:10:37", "published_display": "30 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "The article provides the \"Enterprise value to EBITDA forward\" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It appears to be a financial data snippet from TradingView, which offers various market tools and data for stocks, including detailed financial information.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:10:15", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ANAPTYSBIO For: 29 June By Investing.com", "summary": "This article announces the filing of Form 144 for ANAPTYSBIO (ANAB) on June 29. Form 144 is filed with the SEC when company insiders intend to sell restricted or controlled securities. The article provides the title, date, and company, indicating a standard regulatory filing noti", "url": "https://za.investing.com/news/stock-market-news/form-144-anaptysbio-for-29-june-93CH-4348830", "source_name": "Investing.com South Africa", "published_at": "2026-06-29T23:10:37", "published_display": "29 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB)", "summary": "An affiliate of ANAPTYSBIO, INC (NASDAQ: ANAB) has filed a Form 144 to sell 9,476 shares acquired via a stock option exercise on June 29, 2026. The filing also details multiple common stock dispositions by Dennis Mulroy throughout May and June 2026, including specific share count", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-bb651d29383e.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:16", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits", "summary": "AnaptysBio (NASDAQ: ANAB) is holding its annual stockholders meeting on August 11, 2026, where key items for vote include the election of two Class III directors, ratification of KPMG LLP as the auditor, an advisory Say-on-Pay vote for executive compensation, and an amendment to ", "url": "https://www.stocktitan.net/sec-filings/ANAB/def-14a-anaptysbio-inc-definitive-proxy-statement-78785d49d0b7.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:15", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "This page provides financial information for AnaptysBio, Inc. (NASDAQ: ANAB), specifically focusing on its forward price-to-earnings ratio. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other market data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:10", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell Microcap Index", "summary": "AnaptysBio, Inc. (ANAB) has been removed from the Russell Microcap Index. The company's recent activities include a change in its fiscal year-end, UBS adjusting its price target to $76 with a Buy rating, and reporting earnings for Q1 2026. AnaptysBio also recently appointed Chris", "url": "https://www.marketscreener.com/news/anaptysbio-inc-nasdaqgs-anab-dropped-from-russell-microcap-index-ce7f5fded880f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:39:15", "published_display": "29 Jun 2026 08:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANAPTYSBIO, INC ($ANAB) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOd1lrS0FWZUxZanVqa2J1N2tSejV4ZmpNUGE1azZkOVkxQ3hSOUxhdEdJUlJweW9rSDRldmsxMGFiSl9ZbWc1Mk1aQjczeWRKNVNESFNZLWNoaGtCd1lfWjFvY1dTY1lyUWNXSGJtWE1GeUNiTGRxOEhDMFRfQ0Yza2Q2MFVEeUs4ZURlSFVBOA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth?", "summary": "AnaptysBio (ANAB), a clinical stage biotech company, is drawing attention with its recent performance and current valuation. While its 7.3x Price-to-Sales ratio appears undervalued compared to industry peers, an estimated fair P/S ratio suggests it might be overvalued. A Discount", "url": "https://www.sahmcapital.com/news/content/anaptysbio-anab-draws-valuation-attention-is-the-market-already-pricing-in-future-growth-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-27T07:10:56", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ANAPTYSBIO For: 26 June By Investing.com", "summary": "Investing.com reported on a Form 144 filing for ANAPTYSBIO on June 26, 2026. The article primarily consists of the headline repeated several times and a timestamp, with no further details about the filing itself. It is surrounded by various market data, news headlines, and naviga", "url": "https://ng.investing.com/news/stock-market-news/form-144-anaptysbio-for-26-june-93CH-2576564", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T22:39:11", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANAB (NASDAQ) insider sells 10,000 shares; Mulroy made multiple May\u2013June sales", "summary": "A recent SEC Form 144 filing indicates an insider sale of 10,000 ANAB shares through a stock option exercise on June 26, 2026. The filing also details multiple prior sales by Dennis Mulroy in May and June 2026, including 35,000 shares for $1,848,750 and 20,000 shares for $1,153,0", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-76557ab89ace.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:11", "published_display": "26 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANAB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for AnaptysBio, Inc. (ANAB) stock, including its current price of 64.75 USD, recent performance trends, and analyst price targets. Eight analysts have provided 1-year price forecasts, with a maximum estimate of 95.00 USD and a minimum of 70.00 USD", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:21", "published_display": "26 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. Actuals & Estimates (NASDAQ:ANAB)", "summary": "This article provides an overview of AnaptysBio, Inc. (ANAB) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent increase of 5.81% in 24 hours and a 303.32% increase over the last year, with analysts ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:39:11", "published_display": "26 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. Actuals & Estimates (BIVA:ANAB)", "summary": "This article provides financial actuals and estimates for AnaptysBio, Inc. (ANAB) on the BIVA exchange, including analyst price targets, market capitalization, volatility, and historical earnings performance. It also details upcoming earnings dates and revenue projections, along ", "url": "https://www.tradingview.com/symbols/BIVA-ANAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:23", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master lease", "summary": "AnaptysBio, Inc. has subleased 45,057 rentable square feet of its San Diego facility at 10770 Wateridge Circle to First Tracks Biotherapeutics. This sublease, which began on June 15, 2026, runs for 12 months with an option for First Tracks to extend until April 4, 2028, or for an", "url": "https://www.stocktitan.net/sec-filings/ANAB/8-k-anaptysbio-inc-reports-material-event-3eff1556ab17.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:41:15", "published_display": "23 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio Shifts Fiscal Year-End As Volatile Stock Eyes Growth Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWwycndBMnZWUkVsTEFqTzJ4YjA4b0tlTGNvcHI4WU44YkFSV3Q4aWZlelhrbE81RXJnQ0VhYnBPaFR1SzV0LUs4ZG1KNHRaLVRidTgzU3g4SjZSZ2FzeFlvZDFsaVBFWVY5MHJhTmprN1ZZbzRoSmVSUG5JM0psQ1JFb1l2LVBBOHlwVzlITjJscGFSaEZHMGJZeFN4cHg0ZGVMcXJTQXRGVmVm?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-38-135502178.html", "source_name": "Zacks", "published_at": "2026-05-19T13:55:02+00:00", "published_display": "19 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQaGIxSlNEWnlMamE5ODltZDM4Q0hFVHMxVkxoY0IwRjV6bUx1R014bGtaZUJIN1plRWVKcFhkMWRjdzMzN3BfRmdnc2hveHIyemxNWTBlYWo1ZmhUdm9IRTNoYTdHc0ZaN0JlaFpteUpISjNNbFhRT1ZwQlRrWkpqLTE1NEE4MlhiVVkxak8wc2phaHdWMkV5cnZiREI?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "UBS Adjusts Price Target on AnaptysBio to $76 From $70, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/news/ubs-adjusts-price-target-anaptysbio-135830134.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:58:30+00:00", "published_display": "13 May 2026 13:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio Appoints Chris Murphy as CFO, Owen Hughes to Board", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anaptysbio-appoints-chris-murphy-cfo-135114639.html", "source_name": "MT Newswires", "published_at": "2026-05-11T13:51:14+00:00", "published_display": "11 May 2026 13:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdW9TQ0g4bTZSYTV0NV9pMmQ5UGZYaTZsSG5SeFNETWN2dU5PbDJ6NWFDVzZubnhJUUdlQkdLLWVvTGZoTnh2aEpnU1FNVGVkV212TGVmRml5SjNQUkVsMUZOcElyOWFnNW5lQ1JnamkxVm1qNGpBMVo3SDRBdHMyWVZiUzhOcExKUFdfTjc3ZzRuTDBQWFRnbkczZm9VNUFlcVFidU5IOEIwV2sx?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdUpsVTY4S1dpVzNOU1FBVkxLV0hlbW8xVmVYNFV4OEh6THdKZmZkT2diejJnSU5DZ0VpVXJkb3AycnFoYVJDU2YwS1k0TmQyT3B6VXl3Y19kd25tUWdIVjMwTWMwZnkzak9LTDVucTA5TFUycm5WV1ZIMnhMRG9ydWdPa09HSlV5N1VIQVlTeUlOYkxsNTVxSjBIejR0Rk9pby16akIwUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUTdDSW9WX0NOWWltVE8xTThHa01XbG8ybFZ0OGpPWTZWLTQ2b19CME5EdWNkTE9IYlo4Yk83WXFCTENMSTJGZFhCdUdvblFXZllkQVBRQmxmOGNaLUZhWkxzNGlMeEpwR3RHajExdTNCei11UVNNNWJxd1J3LUpBTXRBdHRDZnpZUGx6TXZEc1B3cGh0N1R3aDI0WHhXa0t2?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTldzcHhxcEhybnBRbkpjRHZQeWY0RUNSRWJMUlphOE4tNzladU9uYnYzR3dKTzVCNHBHR3BWaDYycU44NWljYjR0OTdadTRWOXItR2d1MzZXMkttZlN4dkRzeUcwX3FXUGtUcWFhazhMMWtFVm9odEhJa245T2lVaGZPSHpzcGxHdTcwTG5pR01hbm5BYkI5VXZqamFhQ3hMSTQ4Nm55QzFyLWM?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio CEO to appear at royalty company virtual conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPS3dIcE40ei15aDlKOVFZVTVuazg4NmR3d1J0V1M0Q051QVE1RkI4ZHdEM1BHd0xwa2RIUU1IRVowZ2tTR2hZbHJac1NFTFRMOXVKTXcyS0dIeHhzMlR5U0FKMENRdHhvT25laXl0VjFrRVZHQTJ1R0dfbmJmVGhlV09ZWERkNmFJWHZIZm1ZYTBUNVMzdG5MeWtCTTktbzFKazlPb0VFeEtFYXFSLV9McUtlWHZuUXd1ZlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQY3VxY0Zfa3ZobTRzek53dHJDaTRJUDVOQ285Sk5ZY19aV3dHSGhzc1c5VUVFWXNNYlNfQUVuRlk1N2NIclFpeGNhaGRhWnF1MjQ2QVNDNVd0UkUxU3ZXWXBocUdTaUtIcUwxTlcxV3BjbGF6VlVSZDdvWVRqc2tPNkFvSmNhdTF3amg5aHU3T3BUR29PcTMw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOWE56UHRYNVFWckZPMEFZcHhsTjV0SkZzQTkxT1c1OFNVMXYwZ25NMzJGdy1lUm9jcW9lcDRSTlpIUEtaNXRSQm9CX05UWEdnTG9aZlRYWXpiNFNGNHdmSW1BRl9MSlNHckFSZ1ZpTGtDUGg1bms3Q3c1eGlsdTVGRWtIVE1DMjJUdWJrUWRVT1QxTlFUQnZLanpLOA?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Leerink raises AnaptysBio stock price target to $66 on Jemperli growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPckdmaXY3M1ZGSHVwbGlQU3lscHhIenhUU2dfcjdrT2FZNHQySnRSNFBMV0dFYzhlVWhGS2NWekN3Ylcwbjl1LTZOR0dJNWZDQTRUTWdPdEVIaXQ0Tnh5LVMzRGZxTVJRTk9PdnpDSkpxbWgxZWNWVFpHN0l5RVhJVExfUDcwSS1CanRmTHo0d2V3eGloaXhJMmctVHFWVVpLVHhPcnFaaHc2T1E2UUtRWDhWYURkdGRvUmpYamc2OUJhTVp1cUZZaA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AnaptysBio Announces Completion of Spin-Off and Focus on Managing Jemperli and Imsidolimab Royalties for Shareholder Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOVGdPYmxJUi1ycW1GVGYxQk1vT0FVTFhnVHh4S0xnVUxGZEtINERNWHlnUWQwWjVPeVlLRWxaMVlwMXhGcC1IbVMtdEhaUGlidGJpOTVYeGJhZVN5RmdSTWdjbU5VVlVQT1Vrbm9vRkFoUVZQaDNfajNsOXJWcE1ibGNYYWNSN2hSVHFEbUotNWJoVXIyVWpGRXZfcVAwUDY1SWJ3Mi1HMkNzbmVuaGUwTWk1TE90Z0hQOWZTSk1SakFHYl8ybTdfOEJ3aXNHX1lYMGFDT1dyb3JZTFRNV1ZBY192OWtjcHFJMWFZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNNWZzMDJiWHh0ck9rSnRDOVlGZ01xakljX0M1RHBMeEZHaGY2Q0JmVlpnbHY1M3BMa0F2VkZGZHU4WmJJTTk2NWlKZmtrd3N1a3ZYbjJuS2tkR04xZDFSdHY0YUtaQ3RuX0tCc19TejVIRkdTZWtEYm0zQnFUTkxTRnZFdmtMMmw5R3ZSd3hQTzhoZFgxSjhobHFDVi1uM1RNYVduSnV3?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPR09nY3hjc28yOVVsc3Z2aHNrU1hEMVdGaWtyRzQtTjg1WmJ4MXRsTzFiYkpwWjBydXkxczFrRGlzT0c5Mzh0Y0JFbnQ4b0x3UVk1OXFvdzVSdGlqYnM0WTZfSFZ6eFFNZzhJT2t4OURnUDZuOGs4REdVa1JmLXI5WGdKZkUyanUwM3Y2MGFzRFhHUWd1MkxISFFrdG9LcVpWaHo4Q195WVNJSmVoTG5UczI5ckVxZTR6WFQ0M3YzN2JGZzZIdzdpeU5TclVWNy1JdVRESXRESVhoc1E3VUswbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOMlFSeG9zdWlxbm1zTk9PM1k3Q2E3cUlMZnRuVWFpNVZVR0x0SWxnaUdfTjVFay1senVEOUJ6RmZ4dy1HY1hDSmdFYVkzS2gxN2I0SU5rcXNjRnFFMzk1Rjh1b0FKMzd3YVY4UWo0Y0FPcTFtQ0w4T0licVZyYWVnWHJMZlcwdEJXdW1MMUJUVVg?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "AnaptysBio (NASDAQ:ANAB) Trading 5.3% Higher - Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPZFd4U0FwS2dOOVVsTFlYODdTUnliYlk4ZVFrQ09DOXhNdGh5anBrX3V0cWQ5bUtLNlFFUkNqR3BGMjlqMU5nbzFlN3JsOWNiOUZ1ZFFnM3hIcUNNVURjN2dmT0NMOGk0SGRsemFNUTRKSHBDOW5JVFJfVWtiVGMxdldNVVhZWHdZOFZlS2hWRHU3dk1Ud3QtVzR3Z2pSRE5ONTVIdm5uWTFBNHNk?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T17:00:02+00:00", "published_display": "17 Jul 2026 17:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?", "summary": "AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current p", "url": "https://www.sahmcapital.com/news/content/is-anaptysbio-anab-undervalued-following-its-jemperli-royalty-appeal-and-gsk-trial-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T10:41:34", "published_display": "16 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ:ANAB) Shares Gap Down - What's Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQZ0Iydmh4Y1prbkNzanZObWRmRnhBRWdaSW56Wm5nVlpaT1pBSVMwRV9EVmhFS1pvUDVvc1k2aXV4UEZiZXptY0xMRWdQMkFqQ1dtbXFCRlB1RmdxcUF1RzNmbUJfUjh4aEZub3ZqQnNYNDd4TENDWHZZbDJZdmhaRzQ5bUlKNmlfZnlXaUhPWWtTZDgxdHpFaWFUZmozX3dodkhKSQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-15T16:05:51+00:00", "published_display": "15 Jul 2026 16:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10%", "summary": "AnaptysBio (ANAB) shares fell by 10.8% on July 15, 2026, closing at $55.76, amidst broader market volatility and investor caution in the biotechnology sector. The company, a clinical-stage biotech developing antibody product candidates, has a market capitalization of $1.67 billio", "url": "https://www.gurufocus.com/news/8960404/significant-decline-for-anaptysbio-anab-as-shares-drop-over-10?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T15:16:39", "published_display": "15 Jul 2026 15:16", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75", "summary": "Barclays has reiterated its Buy rating on AnaptysBio (ANAB.US), maintaining a target price of $75. This continued positive outlook suggests the firm sees potential upside for the biotechnology company's stock.", "url": "https://www.moomoo.com/news/post/72922436/barclays-maintains-anaptysbio-anabus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-15T01:41:34", "published_display": "15 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ:ANAB) Shares Down 7% - Time to Sell?", "summary": "AnaptysBio (NASDAQ:ANAB) shares dropped 7% in Tuesday trading, hitting an intraday low of $65.76. Despite a wider-than-expected Q1 loss, analysts maintain a \"Moderate Buy\" rating with an average price target of $81.82, and the company has authorized a $100 billion stock repurchas", "url": "https://www.marketbeat.com/instant-alerts/anaptysbio-nasdaqanab-shares-down-7-time-to-sell-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T18:11:53", "published_display": "14 Jul 2026 18:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes AnaptysBio (ANAB) an Investment Bet?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOTk8tQ3BZX29WNVBmOV9DYjhMTXdEeldxU0w3WTlKS1dGTHdHT0Q3ZUowNE1vX3JlNDIzbUhzcWVEQ1pwb1lsaFZvSmdaZHBleVFTQ2h2S1ZpMUxNTTZmTjNPQ2V0WExrdUQxellXVDdvRkRERDhFS3VtNW56Nll6Z0l3NU5JSFN2WnBteGhJVGY3Wm9yeUZpY0kxYkJSQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-14T14:56:40+00:00", "published_display": "14 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ANAPTYSBIO For: 13 July By Investing.com", "summary": "This article reports on a Form 144 filing for ANAPTYSBIO on July 13. It is a brief, factual announcement from Investing.com, providing no additional details beyond the filing date and company name. The article's content is minimal, serving primarily as an informational update.", "url": "https://ng.investing.com/news/stock-market-news/form-144-anaptysbio-for-13-july-93CH-2597508", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:12:44", "published_display": "13 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise", "summary": "JOE ANTHONY WARE, an insider at AnaptysBio (ANAB), has filed a Form 144 to sell 10,694 shares of common stock with an aggregate market value of $718,333.09. These shares are related to a stock option exercise and are expected to be sold on or after July 13, 2026, on NASDAQ. This ", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-aa9871dfbf36.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:33", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "summary": "AnaptysBio, Inc. (NASDAQ:ANAB) has received a \"Moderate Buy\" consensus recommendation from thirteen brokerages, with an average 12-month price target of $81.82. Analyst ratings have been mixed, with some price target increases and some downgrades, indicating ongoing debate about ", "url": "https://www.marketbeat.com/instant-alerts/anaptysbio-inc-nasdaqanab-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T06:39:20", "published_display": "10 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should AnaptysBio\u2019s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base?", "summary": "AnaptysBio (ANAB) was removed from several Russell indices in June 2026, which may impact its short-term trading liquidity and passive fund ownership. Despite this, the core investment thesis remains centered on its immunology pipeline and collaborations, with ongoing litigation ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/should-anaptysbios-anab-russell-index-removal-prompt-a-rethi", "source_name": "Simply Wall Street", "published_at": "2026-07-08T05:11:23", "published_display": "08 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) Undervalued As Russell Index Deletions Reshape Trading Flows?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. Financial Disclosures & Filings", "summary": "This page provides a comprehensive list of AnaptysBio, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategic decisions. It highlights key events such as earnings reports, corporate presentations, and conference transcr", "url": "https://www.tradingview.com/symbols/TRADEGATE-AN6/documents/", "source_name": "TradingView", "published_at": "2026-07-01T21:09:54", "published_display": "01 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ANAPTYSBIO, INC SEC Filing", "summary": "This article details an SEC Form 144 filing by AnaptysBio, Inc. (ANAB) concerning a proposed sale of securities. The document indicates a neutral filing impact and sentiment, outlining the filer and issuer information, as well as details about the common stock to be sold by Morga", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-c46f3e92c4ec.html", "source_name": "Stock Titan", "published_at": "2026-07-01T09:40:58", "published_display": "01 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "This article provides the enterprise value to revenue forward for AnaptysBio, Inc. (NASDAQ: ANAB). It presents a financial metric related to the company's valuation, indicating its enterprise value relative to its future anticipated revenue. The information is sourced from Tradin", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T23:10:24", "published_display": "30 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio\u2019s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?", "summary": "AnaptysBio (ANAB) was recently removed from several Russell indices and entered a one-year sublease agreement for its San Diego facility. These actions suggest a strategic shift involving optimized real estate commitments and a reframing of its investment narrative. Investors sho", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/is-anaptysbios-anab-index-exit-and-office-sublease-quietly-r", "source_name": "Simply Wall Street", "published_at": "2026-06-30T15:10:37", "published_display": "30 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "The article focuses on the \"Price to book forward\" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It provides a view of this financial indicator on the TradingView platform, noting that the market is closed and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T11:10:37", "published_display": "30 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "The article provides the \"Enterprise value to EBITDA forward\" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It appears to be a financial data snippet from TradingView, which offers various market tools and data for stocks, including detailed financial information.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:10:15", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ANAPTYSBIO For: 29 June By Investing.com", "summary": "This article announces the filing of Form 144 for ANAPTYSBIO (ANAB) on June 29. Form 144 is filed with the SEC when company insiders intend to sell restricted or controlled securities. The article provides the title, date, and company, indicating a standard regulatory filing noti", "url": "https://za.investing.com/news/stock-market-news/form-144-anaptysbio-for-29-june-93CH-4348830", "source_name": "Investing.com South Africa", "published_at": "2026-06-29T23:10:37", "published_display": "29 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB)", "summary": "An affiliate of ANAPTYSBIO, INC (NASDAQ: ANAB) has filed a Form 144 to sell 9,476 shares acquired via a stock option exercise on June 29, 2026. The filing also details multiple common stock dispositions by Dennis Mulroy throughout May and June 2026, including specific share count", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-bb651d29383e.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:16", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits", "summary": "AnaptysBio (NASDAQ: ANAB) is holding its annual stockholders meeting on August 11, 2026, where key items for vote include the election of two Class III directors, ratification of KPMG LLP as the auditor, an advisory Say-on-Pay vote for executive compensation, and an amendment to ", "url": "https://www.stocktitan.net/sec-filings/ANAB/def-14a-anaptysbio-inc-definitive-proxy-statement-78785d49d0b7.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:15", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AnaptysBio, Inc. \u2013 NASDAQ:ANAB", "summary": "This page provides financial information for AnaptysBio, Inc. (NASDAQ: ANAB), specifically focusing on its forward price-to-earnings ratio. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other market data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:10", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell Microcap Index", "summary": "AnaptysBio, Inc. (ANAB) has been removed from the Russell Microcap Index. The company's recent activities include a change in its fiscal year-end, UBS adjusting its price target to $76 with a Buy rating, and reporting earnings for Q1 2026. AnaptysBio also recently appointed Chris", "url": "https://www.marketscreener.com/news/anaptysbio-inc-nasdaqgs-anab-dropped-from-russell-microcap-index-ce7f5fded880f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:39:15", "published_display": "29 Jun 2026 08:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANAPTYSBIO, INC ($ANAB) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOd1lrS0FWZUxZanVqa2J1N2tSejV4ZmpNUGE1azZkOVkxQ3hSOUxhdEdJUlJweW9rSDRldmsxMGFiSl9ZbWc1Mk1aQjczeWRKNVNESFNZLWNoaGtCd1lfWjFvY1dTY1lyUWNXSGJtWE1GeUNiTGRxOEhDMFRfQ0Yza2Q2MFVEeUs4ZURlSFVBOA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth?", "summary": "AnaptysBio (ANAB), a clinical stage biotech company, is drawing attention with its recent performance and current valuation. While its 7.3x Price-to-Sales ratio appears undervalued compared to industry peers, an estimated fair P/S ratio suggests it might be overvalued. A Discount", "url": "https://www.sahmcapital.com/news/content/anaptysbio-anab-draws-valuation-attention-is-the-market-already-pricing-in-future-growth-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-27T07:10:56", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ANAPTYSBIO For: 26 June By Investing.com", "summary": "Investing.com reported on a Form 144 filing for ANAPTYSBIO on June 26, 2026. The article primarily consists of the headline repeated several times and a timestamp, with no further details about the filing itself. It is surrounded by various market data, news headlines, and naviga", "url": "https://ng.investing.com/news/stock-market-news/form-144-anaptysbio-for-26-june-93CH-2576564", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T22:39:11", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANAB (NASDAQ) insider sells 10,000 shares; Mulroy made multiple May\u2013June sales", "summary": "A recent SEC Form 144 filing indicates an insider sale of 10,000 ANAB shares through a stock option exercise on June 26, 2026. The filing also details multiple prior sales by Dennis Mulroy in May and June 2026, including 35,000 shares for $1,848,750 and 20,000 shares for $1,153,0", "url": "https://www.stocktitan.net/sec-filings/ANAB/144-anaptysbio-inc-sec-filing-76557ab89ace.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:11", "published_display": "26 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANAB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for AnaptysBio, Inc. (ANAB) stock, including its current price of 64.75 USD, recent performance trends, and analyst price targets. Eight analysts have provided 1-year price forecasts, with a maximum estimate of 95.00 USD and a minimum of 70.00 USD", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:21", "published_display": "26 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. Actuals & Estimates (NASDAQ:ANAB)", "summary": "This article provides an overview of AnaptysBio, Inc. (ANAB) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent increase of 5.81% in 24 hours and a 303.32% increase over the last year, with analysts ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:39:11", "published_display": "26 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. Actuals & Estimates (BIVA:ANAB)", "summary": "This article provides financial actuals and estimates for AnaptysBio, Inc. (ANAB) on the BIVA exchange, including analyst price targets, market capitalization, volatility, and historical earnings performance. It also details upcoming earnings dates and revenue projections, along ", "url": "https://www.tradingview.com/symbols/BIVA-ANAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:23", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master lease", "summary": "AnaptysBio, Inc. has subleased 45,057 rentable square feet of its San Diego facility at 10770 Wateridge Circle to First Tracks Biotherapeutics. This sublease, which began on June 15, 2026, runs for 12 months with an option for First Tracks to extend until April 4, 2028, or for an", "url": "https://www.stocktitan.net/sec-filings/ANAB/8-k-anaptysbio-inc-reports-material-event-3eff1556ab17.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:41:15", "published_display": "23 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio Shifts Fiscal Year-End As Volatile Stock Eyes Growth Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWwycndBMnZWUkVsTEFqTzJ4YjA4b0tlTGNvcHI4WU44YkFSV3Q4aWZlelhrbE81RXJnQ0VhYnBPaFR1SzV0LUs4ZG1KNHRaLVRidTgzU3g4SjZSZ2FzeFlvZDFsaVBFWVY5MHJhTmprN1ZZbzRoSmVSUG5JM0psQ1JFb1l2LVBBOHlwVzlITjJscGFSaEZHMGJZeFN4cHg0ZGVMcXJTQXRGVmVm?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-38-135502178.html", "source_name": "Zacks", "published_at": "2026-05-19T13:55:02+00:00", "published_display": "19 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQaGIxSlNEWnlMamE5ODltZDM4Q0hFVHMxVkxoY0IwRjV6bUx1R014bGtaZUJIN1plRWVKcFhkMWRjdzMzN3BfRmdnc2hveHIyemxNWTBlYWo1ZmhUdm9IRTNoYTdHc0ZaN0JlaFpteUpISjNNbFhRT1ZwQlRrWkpqLTE1NEE4MlhiVVkxak8wc2phaHdWMkV5cnZiREI?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on AnaptysBio to $76 From $70, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/news/ubs-adjusts-price-target-anaptysbio-135830134.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:58:30+00:00", "published_display": "13 May 2026 13:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio Appoints Chris Murphy as CFO, Owen Hughes to Board", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anaptysbio-appoints-chris-murphy-cfo-135114639.html", "source_name": "MT Newswires", "published_at": "2026-05-11T13:51:14+00:00", "published_display": "11 May 2026 13:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdW9TQ0g4bTZSYTV0NV9pMmQ5UGZYaTZsSG5SeFNETWN2dU5PbDJ6NWFDVzZubnhJUUdlQkdLLWVvTGZoTnh2aEpnU1FNVGVkV212TGVmRml5SjNQUkVsMUZOcElyOWFnNW5lQ1JnamkxVm1qNGpBMVo3SDRBdHMyWVZiUzhOcExKUFdfTjc3ZzRuTDBQWFRnbkczZm9VNUFlcVFidU5IOEIwV2sx?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdUpsVTY4S1dpVzNOU1FBVkxLV0hlbW8xVmVYNFV4OEh6THdKZmZkT2diejJnSU5DZ0VpVXJkb3AycnFoYVJDU2YwS1k0TmQyT3B6VXl3Y19kd25tUWdIVjMwTWMwZnkzak9LTDVucTA5TFUycm5WV1ZIMnhMRG9ydWdPa09HSlV5N1VIQVlTeUlOYkxsNTVxSjBIejR0Rk9pby16akIwUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUTdDSW9WX0NOWWltVE8xTThHa01XbG8ybFZ0OGpPWTZWLTQ2b19CME5EdWNkTE9IYlo4Yk83WXFCTENMSTJGZFhCdUdvblFXZllkQVBRQmxmOGNaLUZhWkxzNGlMeEpwR3RHajExdTNCei11UVNNNWJxd1J3LUpBTXRBdHRDZnpZUGx6TXZEc1B3cGh0N1R3aDI0WHhXa0t2?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTldzcHhxcEhybnBRbkpjRHZQeWY0RUNSRWJMUlphOE4tNzladU9uYnYzR3dKTzVCNHBHR3BWaDYycU44NWljYjR0OTdadTRWOXItR2d1MzZXMkttZlN4dkRzeUcwX3FXUGtUcWFhazhMMWtFVm9odEhJa245T2lVaGZPSHpzcGxHdTcwTG5pR01hbm5BYkI5VXZqamFhQ3hMSTQ4Nm55QzFyLWM?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio CEO to appear at royalty company virtual conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPS3dIcE40ei15aDlKOVFZVTVuazg4NmR3d1J0V1M0Q051QVE1RkI4ZHdEM1BHd0xwa2RIUU1IRVowZ2tTR2hZbHJac1NFTFRMOXVKTXcyS0dIeHhzMlR5U0FKMENRdHhvT25laXl0VjFrRVZHQTJ1R0dfbmJmVGhlV09ZWERkNmFJWHZIZm1ZYTBUNVMzdG5MeWtCTTktbzFKazlPb0VFeEtFYXFSLV9McUtlWHZuUXd1ZlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQY3VxY0Zfa3ZobTRzek53dHJDaTRJUDVOQ285Sk5ZY19aV3dHSGhzc1c5VUVFWXNNYlNfQUVuRlk1N2NIclFpeGNhaGRhWnF1MjQ2QVNDNVd0UkUxU3ZXWXBocUdTaUtIcUwxTlcxV3BjbGF6VlVSZDdvWVRqc2tPNkFvSmNhdTF3amg5aHU3T3BUR29PcTMw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOWE56UHRYNVFWckZPMEFZcHhsTjV0SkZzQTkxT1c1OFNVMXYwZ25NMzJGdy1lUm9jcW9lcDRSTlpIUEtaNXRSQm9CX05UWEdnTG9aZlRYWXpiNFNGNHdmSW1BRl9MSlNHckFSZ1ZpTGtDUGg1bms3Q3c1eGlsdTVGRWtIVE1DMjJUdWJrUWRVT1QxTlFUQnZLanpLOA?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink raises AnaptysBio stock price target to $66 on Jemperli growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPckdmaXY3M1ZGSHVwbGlQU3lscHhIenhUU2dfcjdrT2FZNHQySnRSNFBMV0dFYzhlVWhGS2NWekN3Ylcwbjl1LTZOR0dJNWZDQTRUTWdPdEVIaXQ0Tnh5LVMzRGZxTVJRTk9PdnpDSkpxbWgxZWNWVFpHN0l5RVhJVExfUDcwSS1CanRmTHo0d2V3eGloaXhJMmctVHFWVVpLVHhPcnFaaHc2T1E2UUtRWDhWYURkdGRvUmpYamc2OUJhTVp1cUZZaA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AnaptysBio Announces Completion of Spin-Off and Focus on Managing Jemperli and Imsidolimab Royalties for Shareholder Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOVGdPYmxJUi1ycW1GVGYxQk1vT0FVTFhnVHh4S0xnVUxGZEtINERNWHlnUWQwWjVPeVlLRWxaMVlwMXhGcC1IbVMtdEhaUGlidGJpOTVYeGJhZVN5RmdSTWdjbU5VVlVQT1Vrbm9vRkFoUVZQaDNfajNsOXJWcE1ibGNYYWNSN2hSVHFEbUotNWJoVXIyVWpGRXZfcVAwUDY1SWJ3Mi1HMkNzbmVuaGUwTWk1TE90Z0hQOWZTSk1SakFHYl8ybTdfOEJ3aXNHX1lYMGFDT1dyb3JZTFRNV1ZBY192OWtjcHFJMWFZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNNWZzMDJiWHh0ck9rSnRDOVlGZ01xakljX0M1RHBMeEZHaGY2Q0JmVlpnbHY1M3BMa0F2VkZGZHU4WmJJTTk2NWlKZmtrd3N1a3ZYbjJuS2tkR04xZDFSdHY0YUtaQ3RuX0tCc19TejVIRkdTZWtEYm0zQnFUTkxTRnZFdmtMMmw5R3ZSd3hQTzhoZFgxSjhobHFDVi1uM1RNYVduSnV3?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPR09nY3hjc28yOVVsc3Z2aHNrU1hEMVdGaWtyRzQtTjg1WmJ4MXRsTzFiYkpwWjBydXkxczFrRGlzT0c5Mzh0Y0JFbnQ4b0x3UVk1OXFvdzVSdGlqYnM0WTZfSFZ6eFFNZzhJT2t4OURnUDZuOGs4REdVa1JmLXI5WGdKZkUyanUwM3Y2MGFzRFhHUWd1MkxISFFrdG9LcVpWaHo4Q195WVNJSmVoTG5UczI5ckVxZTR6WFQ0M3YzN2JGZzZIdzdpeU5TclVWNy1JdVRESXRESVhoc1E3VUswbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOMlFSeG9zdWlxbm1zTk9PM1k3Q2E3cUlMZnRuVWFpNVZVR0x0SWxnaUdfTjVFay1senVEOUJ6RmZ4dy1HY1hDSmdFYVkzS2gxN2I0SU5rcXNjRnFFMzk1Rjh1b0FKMzd3YVY4UWo0Y0FPcTFtQ0w4T0licVZyYWVnWHJMZlcwdEJXdW1MMUJUVVg?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 58, "sentiment_summary": {"positive": 16, "negative": 6, "neutral": 36, "score": 54, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 66.39, "latest_week": "2026-07-10", "one_week_move": 4.7, "four_week_move": 18.4, "twelve_week_move": 47.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.146714, "market_dynamics_buy_signal": false, "relative_strength": 67.254205, "fair_value_gap": 205.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 61.0426, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.7% over one week, +18.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 17}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "MarketBeat", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Sahm", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 8}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.7% over one week, +18.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "AnaptysBio (NASDAQ:ANAB) Trading 5.3% Higher - Should You Buy?"}], "updated_at": "2026-07-18T02:12:15.006870+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}